Ascendiant Capital Markets Estimates Aemetis Q3 Earnings

Aemetis, Inc (NASDAQ:AMTX) – Analysts at Ascendiant Capital Markets boosted their Q3 2026 earnings estimates for shares of Aemetis in a report issued on Wednesday, August 19th. Ascendiant Capital Markets analyst E. Woo now expects that the specialty chemicals company will earn ($0.18) per share for the quarter, up from their previous estimate of ($0.22). Ascendiant Capital Markets currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Aemetis’ current full-year earnings is ($0.98) per share. Ascendiant Capital Markets also issued estimates for Aemetis’ Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.85) EPS, Q1 2027 earnings at ($0.16) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.10) EPS and FY2027 earnings at ($0.52) EPS.

Aemetis (NASDAQ:AMTX) last announced its quarterly earnings results on Thursday, August 6th. The specialty chemicals company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.16. The company had revenue of $62.70 million for the quarter, compared to analyst estimates of $67.69 million.

A number of other analysts have also recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aemetis in a research report on Friday, July 17th. Wall Street Zen raised Aemetis from a “sell” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aemetis currently has a consensus rating of “Hold” and an average price target of $11.88.

Aemetis Price Performance

NASDAQ AMTX opened at $1.89 on Tuesday. Aemetis has a 1 year low of $1.30 and a 1 year high of $3.80. The company has a market capitalization of $136.40 million, a PE ratio of -2.08 and a beta of 1.48. The company has a fifty day moving average of $1.70 and a two-hundred day moving average of $2.08.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new position in Aemetis in the second quarter valued at $283,000. Bank of America Corp DE raised its holdings in shares of Aemetis by 148.3% in the first quarter. Bank of America Corp DE now owns 101,486 shares of the specialty chemicals company’s stock valued at $324,000 after buying an additional 60,611 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Aemetis by 10,632.5% during the first quarter. Royal Bank of Canada now owns 8,908 shares of the specialty chemicals company’s stock worth $28,000 after buying an additional 8,825 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Aemetis during the first quarter worth about $272,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of Aemetis during the first quarter worth about $33,000. 27.02% of the stock is owned by hedge funds and other institutional investors.

About Aemetis

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.